Business
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n SAINT LAURENT, Quebec, Oct. 21, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the \"Company\" or \"IntelGenx\") today announced that it has entered into an amended and restated license agreement (the “Agreement”) granting Tetra Bio-Pharma (TSX:TBP)(OTCQB:TBPMF)(“Tetra”), a leader in cannabinoid-derived drug discovery and development, additional exclusive worldwide rights, including the right to manufacture, IntelGenx’s Adversa® mucoadhesive delivery technology. The Adversa® technology is designed to limit first-pass metabolism, improve bioavailability, enhance product stability and reduce gastro-intestinal exposure and side-effects. Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting. Under the terms of the Agreement, Tetra is purchasing the worldwide Adversa® technology rights as it relates to its PPP-002 (Dronabinol) drug product candidate for three undisclosed milestone payments: 45% to be paid on November 15, 2020; 45% to be paid on March 1, 2021, and a final payment of 10% upon successful technology transfer. In addition, Tetra will pay IntelGenx a low single digit royalty on future net sales of Dronabinol mucoadhesive tablets. “This agreement reflects the many potential therapeutic benefits of our Adversa® delivery technology,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “In addition to being particularly well-suited for patients who have difficulty swallowing capsules – a common and unfortunate side effect of chemotherapy – Adversa® offers comparable efficacy to capsules, with a potentially superior side-effect profile.” Steeve Néron, Tetra’s Chief Commercial Officer, commented, “We are looking forward to applying the Adversa® technology to our PPP-002 drug candidate with the goal of providing better therapeutic value for both patients with chemotherapy-induced nausea and vomiting and their caregivers.” About Tetra Bio-Pharma Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with FDA and Health Canada approved clinical programs aimed at bringing novel prescription drugs and tre...